|
HY-119464-10mg
|
MedChemexpress LLC
|
MRL-871 [CAS 1392809-08-3]
|
|
Cancer-programmed cell death
|
|
|
HY-119464-100mg
|
MedChemexpress LLC
|
MRL-871 [CAS 1392809-08-3]
|
|
Cancer-programmed cell death
|
|
|
HY-119464-25mg
|
MedChemexpress LLC
|
MRL-871 [CAS 1392809-08-3]
|
|
Cancer-programmed cell death
|
|
|
HY-119464-5mg
|
MedChemexpress LLC
|
MRL-871 [CAS 1392809-08-3]
|
|
Cancer-programmed cell death
|
|
|
HY-119464-50mg
|
MedChemexpress LLC
|
MRL-871 [CAS 1392809-08-3]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-10mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-100mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-5mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-50mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-B0199-1g
|
MedChemexpress LLC
|
Mycophenolate Mofetil [CAS 128794-94-5]
|
|
Cancer-programmed cell death
|
|
|
HY-B0199-100mg
|
MedChemexpress LLC
|
Mycophenolate Mofetil [CAS 128794-94-5]
|
|
Cancer-programmed cell death
|
|
|
HY-B0199-200mg
|
MedChemexpress LLC
|
Mycophenolate Mofetil [CAS 128794-94-5]
|
|
Cancer-programmed cell death
|
|
|
HY-B0199-5g
|
MedChemexpress LLC
|
Mycophenolate Mofetil [CAS 128794-94-5]
|
|
Cancer-programmed cell death
|
|
|
HY-B0199-1mL
|
MedChemexpress LLC
|
Mycophenolate Mofetil [CAS 128794-94-5] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-B0199S-1mg
|
MedChemexpress LLC
|
Mycophenolate Mofetil-d4 [CAS 1132748-21-0]
|
|
|
|
|
HY-B0199S-5mg
|
MedChemexpress LLC
|
Mycophenolate Mofetil-d4 [CAS 1132748-21-0]
|
|
|
|
|
HY-113332-100mg
|
MedChemexpress LLC
|
Myristoleic acid [CAS 544-64-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-147193-10mg
|
MedChemexpress LLC
|
Nampt-IN-10 (TFA) [CAS 2567724-20-1]
|
|
Cancer-programmed cell death
|
|
|
HY-147193-100mg
|
MedChemexpress LLC
|
Nampt-IN-10 (TFA) [CAS 2567724-20-1]
|
|
Cancer-programmed cell death
|
|
|
HY-147193-25mg
|
MedChemexpress LLC
|
Nampt-IN-10 (TFA) [CAS 2567724-20-1]
|
|
Cancer-programmed cell death
|
|
|
HY-147193-5mg
|
MedChemexpress LLC
|
Nampt-IN-10 (TFA) [CAS 2567724-20-1]
|
|
Cancer-programmed cell death
|
|
|
HY-147193-50mg
|
MedChemexpress LLC
|
Nampt-IN-10 (TFA) [CAS 2567724-20-1]
|
|
Cancer-programmed cell death
|
|
|
HY-B0422-10mg
|
MedChemexpress LLC
|
Nateglinide [CAS 105816-04-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-B0422-100mg
|
MedChemexpress LLC
|
Nateglinide [CAS 105816-04-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-B0422-5mg
|
MedChemexpress LLC
|
Nateglinide [CAS 105816-04-4]
|
|
Neuroscience-Neuromodulation
|
|
